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A B S T R A C T
JM-20 (3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro-1H-pyrido[2,3-b][1,5]benzodiazepine)
is a novel benzodiazepine dihydropyridine hybrid molecule, which has been shown to be a neuroprotective
agent in brain disorders involving glutamate receptors. However, the effect of JM-20 on the functional-
ity of the glutamatergic system has not been investigated. In this study, by using different in vitro
preparations, we investigated the effects of JM-20 on (i) rat brain synaptic vesicles (L-[3H]-glutamate uptake,
proton gradient built-up and baﬁlomycin-sensitive H+-ATPase activity), (ii) rat brain synaptosomes (glu-
tamate release) and (iii) primary cultures of rat cortical neurons, astrocytes and astrocyte–neuron co-
cultures (L-[3H]-glutamate uptake and glutamate release). We observed here that JM-20 impairs
H+-ATPase activity and consequently reduces vesicular glutamate uptake. This molecule also inhibits glu-
tamate release from brain synaptosomes and markedly increases glutamate uptake in astrocytes alone,
and co-cultured neurons and astrocytes. The impairment of vesicular glutamate uptake by inhibition of
the H+-ATPase caused by JM-20 could decrease the amount of the transmitter stored in synaptic vesicles,
increase the cytosolic levels of glutamate, and will thus down-regulate neurotransmitter release. To-
gether, these results contribute to explain the anti-excitotoxic effect of JM-20 and its strong neuroprotective
effect observed in different in vitro and in vivo models of brain ischemia.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
In addition to being a physiologically important excitatory neu-
rotransmitter, glutamate plays a pivotal role in various neurological
disorders including cerebral ischemia. Its levels are increased during
cerebral ischemia with excessive neurological stimulation result-
ing in glutamate-induced neuronal toxicity, known as excitotoxicity,
and thus is considered the triggering spark in ischemic neuronal
damage (Mehta et al., 2013; Nishizawa, 2001).
Glutamate transmission involves its accumulation into secreto-
ry vesicles and their subsequent exocytosis to the extracellular space
(Lin and Scheller, 2000). The accumulation of glutamate in secre-
tory vesicles is mediated by vesicular glutamate transporters
(VGLUTs) (Juge et al., 2010). This process is driven by an electro-
chemical H+ gradient (ΔpH) established by the vacuolar-type ATPases
(V-ATPase) (Maycox et al., 1988; Naito and Ueda, 1985; Nelson and
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Harvey, 1999). It is expected that both the electrochemical driving
force and VGLUT activity affect vesicular glutamate content and sub-
sequent glutamatergic signaling and release (Juge et al., 2010). We
have recently observed that JM-20 (3-ethoxycarbonyl-2-methyl-4-
(2-nitrophenyl)-4,11-dihydro-1H-pyrido[2,3-
b][1,5]benzodiazepine) given 1 h after reperfusion at the
neuroprotective dose of 8 mg/kg signiﬁcantly reduced the gluta-
mate concentration in cerebrospinal ﬂuid from rats subjected to
90 min middle cerebral artery occlusion, compared with vehicle-
treated rats (5.5 ± 1.55 μM versus 14.4 ± 3.48 μM) (Nuñez-Figueredo
et al., 2014b). The glutamate levels in JM-20-treated rats were equiv-
alent to normal values because no difference was observed when
compared to those from a sham-operated group (4.5 ± 1.2 μM). Ad-
ditionally, we identiﬁed the ability of this molecule to selectively
inhibit the hydrolytic activity of mitochondrial F1FO ATP
synthase at very low micromolar concentrations (IC50 = 5 μM)
(Nuñez-Figueredo et al., 2014a). Because V-ATPase and mitochon-
drial F-type ATPase (F-ATPase) have a similar structure and
mechanism of action (Nelson and Harvey, 1999), we hypothesized
that the in vivo anti-excitotoxic effect of JM-20 observed else-
where could be mediated by the inhibition of V-ATPase activity and
the subsequent reduction in quantum release of glutamate into the
synaptic cleft. To prove this hypothesis we evaluated the in vitro
effects of JM-20 on the following preparations: (i) rat brain synap-
tic vesicles (L-[3H]-glutamate uptake, proton gradient built-up, and
V-ATPase activity), (ii) rat brain synaptosomes (glutamate release)
and (iii) primary cultures of rat astrocytes, neurons and astrocyte–
neuron co-cultures (L-[3H] glutamate uptake and glutamate release).
2. Materials and methods
2.1. Compounds and reagents
All chemicals used were of the highest grade available and pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise
speciﬁed. Fetal bovine serum (FBS), Dulbecco’s Modiﬁed Eagle’s
Medium: Nutrient Mixture F-12 (DMEM), fungizone and penicillin/
streptomycin were purchased from Gibco BRL (Carlsbad, CA, USA).
Stock solutions of JM-20 were prepared daily in dimethyl sulfox-
ide (DMSO) and added to the cells in culture, synaptosomes or
synaptic vesicles in reaction media at a 1/1000 (v/v) dilution, re-
spectively. Control experiments contained DMSO at a 1/1000 dilution.
JM-20 was synthesized, puriﬁed and characterized as previously re-
ported (Figueredo et al., 2013).
2.2. Experimental animals
Male Wistar rats (3 months, 200–250 g) maintained on a 12 h
light: 12 h dark schedule at 25 °C, with food and water ad libitum,
were obtained from our local breeding colony. The experimental pro-
tocol followed the “Principles of Laboratory Animal Care” (NIH
publication 85-23, revised 1985) and was approved by the Ethics
Committee for Animal Research of the Federal University of Rio
Grande do Sul.
2.3. Preparation of synaptic vesicles, synaptosomes,
submitochondrial particles and cell cultures from rat brain
2.3.1. Synaptic vesicles
Synaptic vesicles were isolated from rat brains as previously de-
scribed (Porciuncula et al., 2003). Brieﬂy, crude synaptosomal
fractions (P2) were obtained and osmotically lysed by resuspension
(0.8 ml/g fresh tissue) in 10 mM Mops–Tris (pH 7.4) containing
0.1mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetra acetic
acid (EGTA) for 30 min and centrifuged at 32,800 g for 20 min. The
pellet was considered as synaptosomal pellet in order to evaluate
further the quality of synaptic vesicle fraction. The supernatant con-
taining synaptic vesicles was subjected to 0.4 and 0.6 M sucrose
density gradient centrifugation at 65,000 g for 2 h. The synaptic
vesicle fraction was isolated from the 0.4M sucrose band and stored
at −70 °C.
2.3.2. Synaptosomes
The forebrain frommaleWistar rats (3–4months old) was rapidly
removed and homogenized in isolation buffer containing 0.32 M
sucrose, 1 mM EDTA (K+ salt), and 10mM Tris–HCl (pH 7.4). The ho-
mogenate was centrifuged at 1330 g for 3min. The supernatant was
carefully retained and then centrifuged at 21,200 g for 10 min. The
pellet was resuspended and carefully layered on top of a discon-
tinuous Percoll gradient and centrifuged for 5min at 30,700 g (Sims,
1990).
2.3.3. Submitochondrial particles
Rat brain mitochondria were obtained using a discontinuous
Percoll gradient protocol (Sims, 1990). The mitochondrial respira-
tory control ratio (state 3/state 4 respiratory rate ratio) was over
5, measured using 5 mM glutamate and 5 mM malate as NADH-
linked substrates. Submitochondrial particles were obtained by
freezing and thawing (three cycles) isolated mitochondria (20 mg/
ml) as previously described for rat heart mitoplast (Uyemura and
Curti, 1992).
Each preparation (synaptic vesicles, synaptosomes or mitochon-
dria) was obtained from two whole rat brains. The protein
concentrationwas determined using themethod described by Lowry
et al. (1951) with bovine serum albumin as a standard.
The quality of preparations (synaptosomes, and synaptic vesicles)
was evaluated by western blotting, analyzing the immunocontent
of the following proteins: synaptosomal-associated protein 25 (SNAP
25), vesicular glutamate transporter 2 (VGLUT), synaptobrevin
(VAMP), synaptophysin, and vacuolar H+ ATPases (V-ATPase) for syn-
aptic vesicles; excitatory amino acid transporter 1 (GLAST), and
excitatory amino acid transporter 2 (GLT-1), for astrocyte mem-
branes; excitatory amino acid transporter 3 (EAAC1), N-methyl-D-
aspartate receptor subunit NR1 (NR1), and postsynaptic density
protein 95 (PSD95) for neuronal plasma membrane; and mono-
amine oxidase A (MAO A) and succinate dehydrogenase (SDH) for
outer and inner mitochondrial membrane, respectively. High
immunocontent of synaptic vesicle proteins withminimal or/no con-
tamination of other cellular compartments in the synaptic vesicle
preparations was obtained, compared to lysed synaptosomes pellets.
2.3.4. Cell cultures
Primary astrocyte cultures were prepared from the cerebral cortex
of newborn (0–1-day old; P0) Wistar rats, as described previously
(Loureiro et al., 2010). Brieﬂy, rats were decapitated, brain struc-
tures were removed and the meninges were carefully stripped off.
Cells were mechanically dissociated and plated in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM) containing 10% fetal bovine serum
(pH 7.4) supplemented with glucose (33 mM), glutamine (2 mM),
and sodium bicarbonate (3 mM) into a 15.6 diameter well (24-
well plate) that had been coated with polyornithine (1.5 mg/ml,
Sigma, St. Louis, MO). Astrocyte cultures were maintained in an in-
cubator at 37 °C in a humidiﬁed atmosphere of 95% air and 5% CO2.
Cultures were used at 15–20 days in vitro (DIV) with astrocytes
showing a conﬂuent monolayer consisting of >95% of glial ﬁbril-
lary acidic protein (GFAP)-positive cells.
Primary neuronal cell cultures were prepared from the cere-
bral cortices of embryonic day 18Wistar rats, as previously described
(Moura Neto et al., 1983). Approximately 5 × 104 cells were plated
on monolayer carpets of astrocytes for co-culture assays. Neurons
and co-cultures were maintained in vitro for 7 days before being
used in experiments.
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2.4. Glutamate uptake
2.4.1. Vesicular glutamate uptake
Vesicular L-[3H] glutamate uptake was performed in a stan-
dard medium (ﬁnal volume of 200 μl) consisting of 10 mMMops–
Tris, pH 7.4, 4mMKCl, 140mMpotassium gluconate, 0.12M sucrose,
2mMMgCl2, and 2mMATP. Glutamate uptake was determinedwith
50 μM L-[3H] glutamate (Amersham International). Speciﬁc uptake
was calculated by discounting the uptake measured in the absence
of ATP. Radioactivity was measured with aWallac Model 1409 liquid
scintillation counter (PerkinElmer-Wallac, Inc., Gaithersburg, Md).
JM-20 was added at ﬁnal concentrations of 0.1, 1, and 10 μM, based
on previous results (Nuñez-Figueredo et al., 2014a).
2.4.2. Cell culture glutamate uptake
Cell cultures (astrocytes, neurons and co-cultures) were incu-
bated for 15min with an HBSS solution containing (mM): 137 NaCl,
0.63 Na2HPO4, 4.17 NaHCO3, 5.36 KCl, 0.44 KH2PO4, 1.26 CaCl2, 0.41
MgSO4, 0.49 MgCl2 and 5.55 glucose, adjusted to pH 7.4. [3H] glu-
tamate uptake was performed according to Frizzo et al. (2001) with
somemodiﬁcations. Brieﬂy, uptakewas carried out at 35 °C by adding
100 μM unlabeled glutamate and 0.33 μCi/ml L-[3H] glutamate for
5 min. JM-20 (1 and 10 μM) was added 20 min prior to the addi-
tion of L-[3H] glutamate. The reaction was terminated by twowashes
of ice-cold HBSS (4 °C) immediately followed by the addition of 0.5 N
NaOH. Sodium-independent uptake was determined at 35 °C using
HBSS containing N-methyl-D glutamine instead of NaCl and Na2HPO4.
Sodium-dependent uptake was obtained by subtracting sodium-
independent from total uptake. Incorporated radioactivity was
determined with a Packard scintillator (TRI CARB 2100 TR). All ex-
periments were performed in triplicate.
2.5. Vesicular transmembrane proton gradient (ΔpH)
ΔpH was determined by measuring the ﬂuorescence quench-
ing of acridine orange (1.5 μM) in a Spectra Max M5 microplate
reader spectrophotometer as previously described using an exci-
tation wavelength of 492 nm and an emission wavelength of 537 nm
(Goh et al., 2011). The reaction was initiated by the addition of 1mM
MgCl2 in the presence of 1 mM ATP to a reaction medium contain-
ing 30 μg of synaptic vesicle protein, 140mMKCl, and 10mMMops–
Tris (pH 7.4). The reaction was terminated by the addition of Triton
X-100 to a ﬁnal concentration of 10 μM. JM-20 effects were evalu-
ated at 0.1, 1 and 10 μM. The percentage of fractional quench is
calculated according to the following equation: % Fractional
quench = [F(i) − F(MgCl2)]/F(0) × 100, where F(i) is the initial ﬂuores-
cence intensity, and F(MgCl2) and F(0) are the ﬂuorescence intensities
after the addition of MgCl2 and the dissipating detergent, respectively.
2.6. Measurement of V-ATPase and F1F0 ATPase activities
The activities of V-type ATPase (baﬁlomycin-sensitive H+-
ATPase activity) and F1F0 ATPase (oligomycin-sensitive ATPase
activity) were measured in the media used for uptake experi-
ments. Synaptic vesicles or submitochondrial particles (20 μg
proteins) were pre-incubated for 10 min in the presence of 1 μM
baﬁlomycin A1 (for vesicles) or 3 μM oligomycin (for submitochon-
drial particles) (Sigma, St. Louis, MO) with or without JM-20 (0.1,
1, and 10 μM) for 10 min at 35 °C. The incubation was stopped by
the addition of 10% trichloroacetic acid (v/v). Samples were chilled
on ice for 10 min, and 100 μl aliquots were withdrawn for assay-
ing the released inorganic phosphate (Pi) as previously described
(Chan et al., 1986), using malachite green as the color reagent. Con-
trols where the synaptic vesicle or submitochondrial particle
preparations were added after trichloroacetic acid were used for cor-
recting non-enzymatic Pi release. The speciﬁc V-ATPase or F1F0
ATPase activities were calculated by subtracting the total ATPase
activities (in the absence of baﬁlomycin or oligomycin) from the
ATPase activity measured in the presence of such inhibitors.
2.7. Glutamate release in rat brain synaptosomes
Synaptosomes (250 μg) were incubated for 1min with KCl at low
(10 mM) or high (56 mM) concentrations in modiﬁed Hank’s Bal-
anced Salt Solution (HBSS) at 37 °C in the presence of JM-20 (1, 5
and 10 μM). For basal glutamate release, the synaptosomes were
incubated in low-non depolarizing KCl (1.2 mM) HBSS. After, syn-
aptosomes were centrifuged for 10 min at 14,000 g. Supernatants
(25 μl) were used for glutamate determination by high-performance
liquid chromatography (HPLC).
2.8. Glutamate determination by HPLC
The supernatants were derivatized with o-phthalaldehyde and
separation was carried out with a reverse phase column (Supelcosil
LC-18, 250mm × 4.6mm, Supelco) in a Shimadzu Instruments liquid
chromatograph (50 μl loop valve injection). Themobile phase ﬂowed
at a rate of 1.4 ml/min and column temperature was 24 °C. Buffer
compositions were as follows: buffer A: 40mMNaH2PO4 ×H2O buffer,
pH 5.5, containing 20% methanol; buffer B: 10 mM NaH2PO4 ×H2O
buffer, pH 5.5, containing 80% methanol. The gradient proﬁle was
modiﬁed according to the content of buffer B in the mobile phase:
0% at 0.00 min, 25% at 13.75 min, 100% at 15.00–20.00 min, 0% at
20.01–25.00 min. Absorbance was read using 360 nm and 455 nm,
excitation and emission, respectively, with a Shimadzu ﬂuores-
cence detector. Samples of 50 μl were used and concentration was
expressed in μM (Joseph and Marsden, 1986; Schmidt et al., 2009).
2.9. Statistical analysis
The software GraphPad Prism 5.0 (GraphPad Software Inc., USA)
was used for statistical analysis. The data were expressed as the
mean ± SEM. Comparisons between different groups were per-
formed using one-way analysis of variance (ANOVA) followed by
the Newman–Keuls multiple comparison test. Differences were con-
sidered statistically signiﬁcant at P < 0.05.
3. Results
3.1. JM-20 speciﬁcally inhibits Baﬁlomycin-sensitive H+-ATPase and
the hydrolytic activity of F1FOATPase in synaptic vesicles and brain
submitochondrial particles, respectively
In our previous study, we showed that JM-20 inhibits the hy-
drolytic activity of F1FO-ATP synthase in mitochondria and
submitochondrial particles isolated from rat liver (Nuñez-Figueredo
et al., 2014a). Considering that F-ATPases and V-ATPases have struc-
tural and functional similarities, we hypothesized that this molecule
may inhibit V-ATPase activity. Fig. 1 A and B shows that JM-20 in-
hibited the hydrolytic activity of brain mitochondrial F1FO-ATP
synthase and vesicular H+-ATPase activity, in a concentration de-
pendent manner.
3.2. JM-20 prevents the formation of the vesicular ΔpH gradient
In nerve terminals, V-ATPase generates an electrochemical proton
gradient (ΔpH) that is used by speciﬁc neurotransmitter-proton
antiporters to accumulate neurotransmitters inside storage organ-
elles. Seeing that JM-20 inhibited the activity of vesicular H+-
ATPase, we investigated the effects of this molecule on the vesicular
ΔpH formation. Fig. 2Ashows that 0.1–10 μM JM-20 dissipated the
ΔpH gradient formation of synaptic vesicles in a dose dependent
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manner. This process was triggered by the addition of 1 mMMgCl2
in the presence of 1 mM ATP and was terminated by the addition
of 10 μM Triton X-100. The percentage of fractional quench (Fig. 2B)
shows that JM-20 at 10 μM completely inhibited the formation of
the proton gradient across vesicular membranes.
3.3. JM-20 inhibits glutamate uptake by synaptic vesicles
Considering that the vesicular glutamate uptake depends on ΔpH
generated by the H+-ATPase, we investigated the effects of JM-20
on glutamate uptake in synaptic vesicles. Fig. 2C shows that JM-
20 inhibits speciﬁc L-[3H]-glutamate uptake compared with control-
treated synaptic vesicles in a concentration-dependent manner. The
non-speciﬁc glutamate uptake (in the absence of ATP) was not af-
fected by JM-20 (data not shown).
3.4. JM-20 inhibits glutamate release in rat brain synaptosomes
Inhibition of V-ATPase activity and consequent reduction of ΔpH
elicited by JM-20 should decrease the amount of transmitter stored
in synaptic vesicles and thus down-regulate transmitter release.
Fig. 3shows that JM-20 dose dependently and in the low nanomolar
range inhibited glutamate release (P < 0.05) by synaptosomes evoked
by high (Panel A_56 mM) or low (Panel B_10 mM) KCl concentra-
tions. Stimulating synaptosomes with low concentrations of KCl
appears to uncover additionalmechanism of release inhibition, which
is dependent on Na+ or K+-channel-driven depolarization (Godino
et al., 2007). The similar pattern of glutamate release inhibition ob-
served at both depolarizing conditions suggests that JM-20 acts
mainly on vesicular glutamate release (Ca2+-dependent). Further-
more, this molecule did not interfere with the neurotransmitter
release under basal non-depolarizing condition (result not shown).
3.5. JM-20 affected glutamate uptake in astrocytes and
astrocyte–neuron co-cultures but not in neurons cultures
Astrocytes protect neurons through multiple mechanisms, in-
cluding regulation of ionic homeostasis, control of extracellular
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glutamate levels, and upregulation of glycolytic capacity during isch-
emia (Dienel and Hertz, 2005). In our experimental conditions, JM-
20 did not stimulate glutamate uptake in neurons (Fig. 4B) but
increased it in cultured astrocytes (Fig. 4A) at very low micromo-
lar concentrations (0.01–1 μM). A strong tendency to increase the
neurotransmitter uptake by JM-20 was also observed in neurons–
astrocytes co-culture, being statistically signiﬁcant at 1 μM. (Fig. 4C).
Under the same experimental conditions, JM-20 (0.01, 0.1, 1 and
10 μM) did not induce glutamate release in any of the indepen-
dent cultures used (Fig. 4D–F).
4. Discussion
Glutamate is a major excitatory neurotransmitter working at a
variety of excitatory synapses in the nervous system. Pharmaco-
logical studies in rodents and recent clinical studies in humans have
shown that the extracellular concentration of glutamate increases
to neurotoxic levels in ischemia (Kostandy, 2012; Lai et al., 2014;
Nishizawa, 2001). Glutamate is believed to contribute to neuronal
damage in humans suffering from acute degenerative disorders such
as stroke (Chan et al., 1986; Chao et al., 2010). Glutamate stimu-
lation of α-amino-3-hydroxy-5-methyl-4-isoxazolone-proprionic acid
(AMPA) receptors increases sodium uptake by neurons, contribut-
ing to cellular edema. However, glutamatergic stimulation of
N-methyl-D-aspartate (NMDA) receptors by glutamate increases in-
tracellular calcium concentrations and cell death (Weinberger, 2006).
Despite the extensive and continued research focusing on themecha-
nisms of excitotoxicity, there are currently no pharmacological
interventions capable of providing signiﬁcant neuroprotection in pa-
tients suffering from brain ischemia or injury (Puyal et al., 2013).
Although the results in human trials have not been positive, they
have advanced the understanding of neuroprotection in ischemic
stroke treatment and revealed better strategies for conducting clin-
ical trials in this area (Weinberger, 2006). In this sense, efforts have
been made to reduce glutamate levels during earlier stages of
excitotoxicity by inhibiting synthesis or release. Thus, compounds
that block the uptake of glutamate into synaptic vesicles may reduce
excitotoxic events (Thompson et al., 2005). In this work we have
observed that JM-20 inhibited glutamate uptake by synaptic vesicles
in association with an inhibition of V-ATPase activity and a dissi-
pation of ΔpH. These related effects may contribute to the reduction
of glutamate quantal size, thus reducing the glutamate released into
the synapses, and could partly explain the anti-excitotoxic effect we
recently observed in vivo (Nuñez-Figueredo et al., 2014b).
An apparent divergent effect of JM-20 on glutamate release in
synaptosomes (inhibition) and the cell culture (no effect) was ob-
served. Unlike primary cell culture, synaptosomal fraction from
whole brain is not homogeneous. Indeed, different populations of
synaptic-like vesicles from rat brain with marked biochemical het-
erogeneity have been described (Provoda et al., 2000; Thoidis et al.,
1998). Thus the dissimilar effects of JM-20 on primary culture of
cortical neurons and synaptosomes suggest that the observed phar-
macological effects of this molecule are related not only to its action
toward a speciﬁc neuronal cell type, but also to a more complex
mechanism involving different components of the neurovascular unit.
We also observed that JM-20 inhibited glutamate release in a
more complex brain synaptosome system, which represents an ex-
cellentmodel to study the effects of substanceswith potential activity
in the central nervous system. Because this effect was observed
during K+-evoked glutamate release, it could result from different
mechanisms of action of this molecule: (i) it is inhibiting the Na+-
dependent glutamate transporters (EAATs) located on the plasma
membrane of neurons and glial cells, or (ii) it does not affect such
transporters but is instead diminishing the amount of glutamate
released by the vesicular-mediated effects described above. The latter
mechanism may increase the cytosolic levels of glutamate, which
in turnmay downregulate the transmitter release and also its uptake.
It is worth noticing that non vesicular glutamate accumulation (i.e.
cytosolic) may contribute to elevate extracellular glutamate con-
centration through cystine/glutamate antiporter (Soria et al., 2014).
In this sense, it would appear that the vesicular glutamate trans-
port inhibition by JM-20 would further aggravate the excitotoxicity,
rather than protect it. It has been observed that the increased spon-
taneous vesicular transmitter release caused by energy depletion
or baﬁlomycin A1 only leads to extracellular glutamate accumula-
tion when glial glutamate uptake is blocked (Gebhardt et al., 2002;
Jabaudon et al., 2000; Soria et al., 2014). We observed here that JM-
20 enhanced glutamate uptake in astrocyte culture alone at very
low micromolar concentrations, but it did not, in cortical neurons.
Because the astrocytic glutamate transport plays a major role in
maintaining extracellular glutamate concentrations below neuro-
toxic levels (Anderson and Swanson, 2000; Danbolt, 2001), and the
neurotransmitter uptake by astrocytes can be stimulated by several
neuroprotective compounds (Beller et al., 2011; Karki et al., 2014;
Wu et al., 2008), the above mentioned effects of JM-20 may con-
tribute to explain its anti-excitotoxic actions in vitro
(Nuñez-Figueredo et al., 2014a) and in vivo (Nuñez-Figueredo et al.,
2014b).
Astrocytes actively shape the dynamics of neurons and neuro-
nal ensembles by affecting several aspects critical to neuronal
function, such as regulating synaptic plasticity, modulating neuro-
nal excitability, and maintaining extracellular ion balance (Volman
et al., 2012). Thus, there is an active and bi-directional interaction
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Fig. 3. Effects of JM-20 (1, 5, and 10 μM) on synaptosomal glutamate. Synapto-
somes were incubated for 1 minute with high (56 mM) (A), or low (10 mM) KCl (B)
in HBSS at 37 °C in the absence (Control) or presence of JM-20 (1, 5 and 10 μM). After
incubation, synaptosomes were centrifuged for 10 min at 14,000 g. Supernatants
(25 μl) were used for glutamate determination by high-performance liquid chro-
matography (HPLC). The results are expressed as the means ± S.E.M. of 3 independent
vesicle preparations. Statistically signiﬁcant differences from controls are repre-
sented by #p < 0.05 according to ANOVA and post hoc Newman–Keuls tests.
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between glia and neurons that challenges any in vitro results ob-
tained with neurons or astrocytes in culture alone. In this sense, we
observed that like in astrocytes, JM-20 increased glutamate uptake
in cortical neurons/astrocytes co-culture. This suggests that hith-
erto unidentiﬁed astrocyte-derived factors may be responsible for
the JM-20 effects, either by eliciting direct neuroprotective effects
or by modulating the microglial response to neuronal injury.
In summary, JM-20 seems to exert a modulatory action on the
glutamatergic system by inhibiting the vesicular ATPase activity,
which in turn prevents the establishment of the electrochemical
proton gradient across the vesicular membrane, with a marked in-
hibition of glutamate uptake. JM-20 also inhibited glutamate release
in synaptosomal membranes. Additionally, JM-20 increased gluta-
mate uptake in astrocyte culture alone or co-cultured with neurons,
an effect probably mediated by the glial cells signals. These actions
may contribute to the maintenance of extracellular glutamate con-
centrations below neurotoxic levels. Finally, these results provide
further evidence of the neuroprotective potential of JM-20 in pa-
thologies that involve excessive glutamate release, such as cerebral
ischemia, and contribute to the explanation of the anti-excitotoxic
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effect of JM-20 observed in vivo (Nuñez-Figueredo et al., 2014b). Un-
fortunately, even though animal models demonstrate dramatic
histological and behavioral neuroprotection with JM-20
(Nuñez-Figueredo et al., 2014b), no pharmacological intervention
with drugs that affect glutamatergic transmission has yet been shown
to provide beneﬁt in humans, and toxicity remains a large obsta-
cle (Lau and Tymianski, 2010; Muir, 2006). Thus, the clinical
usefulness of JM-20 will also depend on its acute and chronic side
effects. Indeed, because the ﬁlling of synaptic vesicles with mono-
amines also depends on the energy stored in a H+ electrochemical
gradient produced by the vacuolar-type H+-ATPase (Hnasko and
Edwards, 2012), JM-20 could interfere with monoaminergic trans-
mission by affectingmonoamines vesicular loading as well. Increased
cytosolic accumulation due to the perturbation of catecholamine
accumulation into storage vesicles could cause increased oxida-
tive stress and oxidative damage to the catecholaminergic neurons
(Adams et al., 2001; Liu and Edwards, 1997). Thus, the potential neu-
rotoxic and addictive effects of JM-20 related to its potential
impairment of monoaminergic transmission need to be addressed.
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